MET Enhances Amivantamab Binding to EGFR and Antibody-Dependent Cellular Toxicity. Sato S, Yilmaz N, Arai S, Sakai K, et al. Cancer Sci 2026;117:118-129.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Sato S, Yilmaz N, Arai S, Sakai K, et al. MET Enhances Amivantamab Binding to EGFR and Antibody-Dependent Cellular Toxicity. Cancer Sci 2026;117:118-129.
PMID: 41206690